Cirrhosis future or investigational therapies

Cirrhosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cirrhosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Tertiary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case studies
Case #1
Cirrhosis future or investigational therapies On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cirrhosis future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cirrhosis future or investigational therapies
CDC on Cirrhosis future or investigational therapies
Cirrhosis future or investigational therapies in the news
Blogs on Cirrhosis future or investigational therapies
Directions to Hospitals Treating Cirrhosis
Risk calculators and risk factors for Cirrhosis future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-In-Chief: Ujjwal Rastogi, M.B.B.S. [2]

Future or Investigational Therapies

The following therapies are under trial:

• Obeticholic acid (OCA) for patients with primary biliary cirrhosis.
• Boehringer Ingelheim’s investigational direct-acting antiviral compounds: BI 201335 (protease inhibitor plus BI 207127 (polymerase inhibitor)